ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO669

Maintenance Intravenous Iron in Hemodialysis Patients to Minimize Erythropoietin Doses: A Double-Blinded, Randomized Controlled Trial

Session Information

  • Anemia and Iron Metabolism
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Tantiyavarong, Pichaya, Thammasat University Faculty of Medicine, Khlong Nueng, Pathum Thani, Thailand
  • Anumas, Suthiya Anumas, Thammasat University, Pathum Thani, Pathum Thani, Thailand
  • Chatkrailert, Aphichat, Thammasat University Hospital, Khlong Nueng, Pathum Thani, Thailand

There is no standard regimen for maintenance iron supplementation in chronic hemodialysis patients. We investigated fixed-appropriate doses of intravenous (IV) iron protocols for maintaining hemoglobin levels and minimizing erythropoietic-stimulating agents (ESA).


A double-blinded, randomized controlled trial was conducted in hemodialysis patients who had ferritin levels of 200-700 ng/dl and transferrin saturation (TSAT) 20-40%. Patients were randomized to receive either 100-mg or 200-mg monthly IV iron. ESA was adjusted monthly to maintain Hb of 10-12 g/dl. The primary endpoint was ESA dose at 12 months. Key secondary endpoints were all-cause mortality, cardiovascular events, absolute iron deficiency anemia (IDA), blood transfusion, adverse events, and iron withholding rate.


Of 79 eligible patients, 40 were in the 100-mg IV iron group and 39 in the 200-mg. Mean monthly ESA dose at month 12 was 35,706 ± 21,637 IU in the 100-mg IV iron group versus 26,382±14,983 IU in the 200-mg group (P = 0.03). Twelve patients (30%) in 100-mg group and four patients (10.5%) in 200-mg one had IDA (P = 0.05). Three patients in each group died (P = 0.9). There were no significant differences in hospitalization, venous access thrombosis, and infection rate in both groups, but these were slightly higher in the 200-mg cohort. The withholding rate was 25% and 64.1% (P = 0.03).


Monthly 200-mg IV iron doses were effective at minimizing ESA doses in hemodialysis patients but with a higher withholding rate. In high-ferritin patients, we suggest starting with 100-mg IV iron.

Mean monthly dosages of erythropoietin at month 0 (baseline), month 6, and month 12 (primary endpoint) between 100-mg and 200-mg intravenous iron groups